Chimeric Therapeutics Raises $2.7m in shortfall placement
- Chimeric Therapeutics (CHM) announces details of its retail entitlement offer shortfall placement after failing to raise its intended $18.1M in the entitlement offer
- Chimeric said that in consultation with its lead manager and co-manager, it had raised around $2.7m via 15.9m shares at 17 cents
- The company will not seek to conduct any further shortfall placements relating to the entitlement offer, which raised around $14.4M before costs
- Since the announcement of the entitlement offer, Chimeric has continued to make important advancements across its business and cell therapy portfolio
- CHM shares are up 1.67 percent, trading at 15.3 cents
